Navigation Links
FDA Warning Letter to Genzyme Related to the Allston Manufacturing Facility
Date:3/3/2009

Has No Foreseeable Impact on Aldurazyme Sales

NOVATO, Calif., March 3 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that the FDA warning letter issued to Genzyme addressing deficiencies related to Genzyme's Allston Landing manufacturing facility during an inspection performed in September and October 2008 has no foreseeable impact on the supply of Aldurazyme. The warning letter does not require Genzyme to recall or quarantine product. BioMarin and Genzyme have sufficient quantities of finished product on hand to meet current demand and can fill additional product at a qualified alternate fill finish supplier. BioMarin is also qualifying a third supplier, which it expects to be approved later this year and has no concerns on maintaining sufficient levels of Aldurazyme inventory. BioMarin does not expect that the situation at the Allston manufacturing facility will have any impact on Aldurazyme sales.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase 1 clinical development for the treatment of PKU. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the fill finish production of Aldurazyme and the expectations of revenue and sales related to Aldurazyme. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: future possible complications with the manufacture of or supply chain for Aldurazyme; Genzyme Corporation's success in continuing the commercialization of Aldurazyme; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2008 Annual Report on Form 10-K, and the factors contained in BioMarin's reports on Form 10-Q. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin(R), Naglazyme(R) and Kuvan(R) are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

    Contact:

    Investors:                                  Media:
    Eugenia Shen                                Susan Berg
    BioMarin Pharmaceutical Inc.                BioMarin Pharmaceutical Inc.
    (415) 506-6570                              (415) 506-6594


'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Campaign for Americas Future Memorandum: Katrina Storm Warning
2. Jump in Youth Suicide Prompts National Childrens Charity KidsPeace to Issue Tips on Prevention, Warning Signs
3. Mayo Clinic study finds FDA warning against antinausea drug droperidol unnecessary
4. Common Early-Warning Symptoms of Ovarian Cancer Identified in CDC/Thomson Healthcare Study
5. Defib Wire Warning Shouldnt Worry Most Users: Experts
6. India, UK Join Growing List of Countries to Require Pictorial Tobacco Warnings
7. Thoratecs ITC Division Receives FDA Warning Letter
8. FDA Issues New Warnings for Anemia Drugs
9. Warning for women who binge drink
10. Avandia Label to Get Heart-Attack Warning
11. FDA Mulls Tougher Warning Label on Kids Flu Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... Achieve TMS West, ... opening a new office in San Clemente, California this month. Achieve TMS West ... California, successfully treating individuals struggling with major depression. Depression impacts over 15 million ...
(Date:1/17/2017)... ... January 17, 2017 , ... Peoples Health is ... Health network on Dec. 1, 2016. Peoples Health, a Metairie-based Medicare Advantage company, ... an exciting addition to our provider network, and the addition will benefit our ...
(Date:1/17/2017)... ... January 17, 2017 , ... SensorInsight ®, ... Sigfox in the U.S.A. to offer Internet of Things (IoT) solutions based ... large-scale environmental sensor deployments such as monitoring solutions used to detect potentially hazardous ...
(Date:1/17/2017)... ... January 17, 2017 , ... SC&H Group, a leading audit, tax, ... in its IT Advisory Services practice . Rossi is the third technology consulting ... for strategic IT guidance grows, and the practice continues to expand.     , Bringing more ...
(Date:1/17/2017)... ... 17, 2017 , ... Physicians Education Review®, LCC (PER®) announces ... for the 34th Annual Miami Breast Cancer Conference®, on March 9-12, 2017 at ... Talamo, said, “We are delighted to have Sandra Lee join us as our ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... YORK , Jan. 17, 2017 The ... 8.02 billion by 2021 from USD 6.35 billion in ... factors driving the growth of this market are rising ... demand for minimally invasive surgeries. The global ... procedure, application, and region. On the basis of type, ...
(Date:1/17/2017)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced ... Phase 3 clinical trial comparing the efficacy and safety ... prevention of hepatic veno-occlusive disease (VOD) in adult and ... are at high risk or at very high risk ... conducted across approximately 100 medical centers in ...
(Date:1/17/2017)... -- Market Research Future published a Half Cooked Research Report on Endoscopy ... USD 33.6 million during the period 2016 to 2022 from USD ... ... been examined as a swiftly growing market and expected to grow ... device in various regions.  The increasing growth in endoscopy procedures is ...
Breaking Medicine Technology: